IL2 and neoplasm: In contrast, the IL-2 blocking antibodies such as Daclizumab (32) and Basilixumab (33) used in the clinics as immunosuppressive agents, showed inferior anti-tumor efficacy as compared to non IL-2 blocking RG6292 in preclinical models (17).